Hemostasis profiling in women with paranoid schizophrenia before and after antipsychotic treatment using the Fibrinodynamics method

Hemostatic abnormalities may contribute to the pathophysiology of schizophrenia, but their relationship with clinical symptoms and changes during inpatient treatment remains insufficiently understood. To evaluate overall coagulation, fibrinolysis, and hemostasis potentials in female patients with paranoid schizophrenia before and after inpatient therapy, and to examine their associations with clinical status. Fifty women with paranoid schizophrenia (mean age, 31.9 ± 10.3 years) were examined before and after inpatient treatment. Hemostasis was evaluated using the Fibrinodynamics method, including overall coagulation potential (OCP), overall hemostasis potential (OHP), overall fibrinolysis potential (OFP), and OFP%. Reference intervals were derived from 45 healthy volunteers. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and Hamilton Depression Rating Scale (HDRS). Before treatment, patients had increased OCP, OHP, and OFP compared with reference values, whereas OFP% remained within the reference interval, indicating increased but relatively balanced coagulation and fibrinolytic activity. Following treatment, PANSS and HDRS scores decreased significantly; however, FD parameters did not change significantly. All hemostatic indices remained elevated relative to controls, while OFP% increased beyond the reference interval, suggesting greater inter-individual imbalance between procoagulant and profibrinolytic activity. Several FD parameters correlated with PANSS and HDRS scores before and after treatment. Women with paranoid schizophrenia demonstrated elevated coagulation and fibrinolytic potentials and a potentially unstable hemostatic balance. Despite clinical improvement, inpatient psychopharmacotherapy was not associated with normalization of hemostatic parameters. The associations between FD indices and psychopathological symptoms support a link between hemostasis and clinical manifestations of schizophrenia. Not applicable.